Luxembourg vs Tuvalu: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Luxembourg
97.0%
in 2025
Tuvalu
97.0%
in 2025
Luxembourg rank
16th
Tuvalu rank
16th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Luxembourg
- Tuvalu
How they compare
Luxembourg currently reports 97.0% against 97.0% in Tuvalu, a difference of 0.0%.
The two have swapped places 1 time across 18 shared years of data; in 2008 it was Luxembourg ahead.
Luxembourg ranks 16th and Tuvalu ranks 16th of 192 countries.
Luxembourg has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Luxembourg | Tuvalu | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 86.0% | 0.0% | 86.0% | Luxembourg |
| 2010s | 93.4% | 0.0% | 93.4% | Luxembourg |
| 2020s | 96.7% | 62.5% | 34.2% | Luxembourg |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Luxembourg or Tuvalu?
- Luxembourg, at 97.0% against 97.0% in Tuvalu as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Luxembourg and Tuvalu?
- 0.0%, with Luxembourg ahead.
- How many years of comparable data are there for Luxembourg and Tuvalu?
- 18 years are reported by both, from 2008 to 2025.
- How do Luxembourg and Tuvalu rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Luxembourg ranks 16th and Tuvalu ranks 16th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.